28 results
6-K
EX-99.1
GMDAQ
Gamida Cell Ltd
19 Jun 19
Gamida Cell and Lonza Establish Commercial Manufacturing Agreement for Omidubicel
6:02am
Santagostino, SVP, head of cell & gene technologies at Lonza. “We seek to partner with such innovative companies who are pioneering important new treatment … by supporting our customers to deliver innovative medicines that help treat or even cure severe diseases.
Patients and consumers benefit from our ability
8-K
EX-99.1
GMDAQ
Gamida Cell Ltd
31 Jan 22
Gamida Cell Announces Appointment of Anat Cohen-Dayag and Naama Halevi-Davidov to its Board of Directors
4:31pm
and development company advancing an innovative immuno-oncology pipeline originating from the company’s computational discovery platforms. Prior
8-K
EX-99.1
GMDAQ
Gamida Cell Ltd
10 Jun 22
Departure of Directors or Certain Officers
7:30am
its truly innovative NAM-technology to develop potentially curative cell therapy candidates,” said Dr. Borrello. “I believe the Company’s novel
8-K
EX-99.1
GMDAQ
Gamida Cell Ltd
19 Sep 22
Departure of Directors or Certain Officers
7:06am
in
Commercializing Innovative Therapies
Julian Adams, Ph.D., to Retire and Remain on the Board as Planned Succession
Boston, Mass. – September 19, 2022 – Gamida
8-K
GMDAQ
Gamida Cell Ltd
31 Jan 22
Gamida Cell Announces Appointment of Anat Cohen-Dayag and Naama Halevi-Davidov to its Board of Directors
4:31pm
provider in the field of computational biology to a therapeutic discovery and development company advancing an innovative immuno-oncology pipeline
8-K
EX-99.1
zxvids
17 Apr 23
Gamida Cell’s Allogeneic Cell Therapy Omisirge® (omidubicel-onlv) Receives FDA Approval
5:29pm
DEF 14A
gyrys v963
22 Jun 22
Definitive proxy
4:22pm
PRE 14A
7u8m1znndqhs1
10 Jun 22
Preliminary proxy
4:25pm
10-K
hki 8ofblp2g2yuxc7gx
24 Mar 22
Annual report
7:30am
10-Q
e5czyf7xm0fzo2 0cg
12 May 22
Quarterly report
7:42am
20-F
6fgxz u03u86d9nv3d
25 Feb 19
Annual report (foreign)
5:08pm
F-1/A
gb1 6o3iwsa16e5pqo
17 Oct 18
Registration statement (foreign) (amended)
6:06am